After reporting promising outcomes from a canine osteosarcoma clinical trial in late 2018, ELIAS is now successfully recruiting specialty hospitals across the country. According to Tammie Wahaus, CEO, 15 specialty hospitals are now certified to offer ELIAS Cancer Immunotherapy (ECI®) both in the Corridor and on the Coasts. The company is projecting that number will exceed 100 hospitals by end of year.

ELIAS is finding strong receptivity for the product amongst specially trained veterinary oncologists due to the outcomes reported for the trial conducted at the University of Missouri which saw 10 dogs complete the treatment protocol.  Outcomes observed included complete and partial responders with remission of metastatic disease or stasis of metastatic disease progression in some patients. Median survival time in that study was reported as 415 days (50% greater than historical results using chemotherapy), where 5 of the 10 dogs are still living with no evidence of disease. Survival times for these 5 dogs is approaching 2 years since diagnosis, ranging from 525 - 731 days as of March 2019. These impressive results were achieved without the use of chemotherapy or radiation. Peer-reviewed publication of the study results is expected later this year.

The Company also recently welcomed Dr. Jeff Bryan, DVM, MS, PhD, DACVIM(Oncology) as the newest member of its Scientific Advisory Board. Dr. Bryan is a Professor of Oncology and Director of the Comparative Oncology Radiobiology and Epigenetics Laboratory at the College of Veterinary Medicine, University of Missouri.

For more information on ELIAS Animal Health, please visit us at

https://eliasanimalhealth.com/